Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Hyoung Kim, Haineng Xu, Erin George, +18

Nature Communications

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <i>BRCA</i> -Mutant Ovarian Cancer Models

Hyoung Kim, Erin George, Ryan L. Ragland, +7

Clinical Cancer Research

RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance

Yifan Wang, John J. Krais, Andrea J. Bernhardy, +8

Journal of Clinical Investigation

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

Haineng Xu, Erin George, Yasuto Kinose, +18

Cell Reports Medicine

Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome

Erin George, Thomas J. Herzog, Alfred I. Neugut, +5

Gynecologic Oncology

Surgical OncologyMedicineNatural HistoryPathologyGynecology +6

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers

Erin George, Hyoung Kim, Clemens Krepler, +20

JCI Insight

Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells.

Karen Nelson, Erin George, Christina D. Swenson, +2

The Journal of Immunology

HistocompatibilityImmunologyPathologyAntigen ProcessingImmune Cell Therapy +18

One Step at a Time: Self-Management and Transitions Among Women With Ovarian Cancer

Dena Schulman‐Green, Elizabeth H. Bradley, Nicholas R. Nicholson, +3

Oncology nursing forum

Safety and Tolerance of Radical Hysterectomy for Cervical Cancer in the Elderly

Erin George, Ana I. Tergas, Cande V. Ananth, +6

Gynecologic Oncology

Gynecologic SurgerySurgical OncologyCervical Cancer ManagementCervical CancerGynecological Surgery +9

Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target

Stefano Pierini, János L. Tanyi, Fiona Simpkins, +6

JCI Insight